NASDAQ:ECYT
Delisted

Endocyte Fund Forecast

$23.99
+0 (+0%)
At Close: Jan 18, 2019
RSI low/high Values: [ 25 - 80 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.

Endocyte fund price ended at $23.99 on Friday, after losing 0%.
(Updated on Jan 18, 2019)

Buy or Hold candidate since Nov 02, 2018 Gain 1.61% PDF

No changes to the price of Endocyte fund on the last trading day (Friday, 18th Jan 2019). During the last trading day the fund fluctuated 0% from a day low at $23.99 to a day high of $23.99. The price has been going up and down for this period, and there has been a 0% change for the last 2 weeks.

The fund lies in the middle of a narrow and weak rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the fund is expected to rise 2.44% during the next 3 months and, with a 90% probability hold a price between $24.31 and $24.91 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

ECYT Signals & Forecast

The Endocyte fund holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $23.99 and $23.91. A breakdown below any of these levels will issue sell signals. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Wednesday, December 19, 2018, and so far it has fallen -0.0417%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell on the last day without any changes to the price. This does not cause any direct divergence but may be an early warning and a possible "turning point". The very low volume increases the risk and reduces the other technical signals issued.

Support, Risk & Stop-loss for Endocyte fund

Endocyte finds support from accumulated volume at $23.85 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

In general the fund tends to have very controlled movements and therefore the general risk is considered very low. However, be aware of low or falling volume and make sure to keep an eye on the fund During the last day, the fund moved $0 between high and low, or 0%. For the last week the fund has had daily average volatility of 0%

Our recommended stop-loss: $23.03 (-4.00%) (This fund has low daily movements and this gives low risk. There is a sell signal from a pivot top found 20 days ago.)

Trading Expectations (ECYT) For The Upcoming Trading Day Of Tuesday 22nd

For the upcoming trading day on Tuesday, 22nd we expect Endocyte to open at $23.99, and during the day (based on 14 day Average True Range), to move between $23.96 and $24.02, which gives a possible trading interval of +/-$0.0257 (+/-0.11%) up or down from last closing price. If Endocyte takes out the full calculated possible swing range there will be an estimated 0.21% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $24.00 (0.04%) than the support at $23.85 (0.58%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is Endocyte fund A Buy?

Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Endocyte fund to perform well in the short-term.

Current score: 3.030 Buy Candidate Unchanged

Predicted Opening Price for Endocyte of Tuesday, January 22, 2019

Fair opening price January 22, 2019 Current price
$23.99 ( 0%) $23.99

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for ECYT

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 23.99 .
R2 23.99 .
R1 23.99 .
Current price: 23.99
Support S1 23.99 .
S2 23.99 .
S3 23.99 .

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 0 .
R2 0 .
R1 24.00 0.0417 %
Current price 23.99
Support S1 23.85 -0.584%
S2 23.63 -1.50%
S3 23.48 -2.13%

FAQ

What is the symbol for Endocyte Fund and on which exchange is it traded?
The symbol for Endocyte is ECYT and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Endocyte Fund?
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Endocyte fund to perform well in the short-term.

How to buy Endocyte Fund?
Endocyte Fund can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Endocyte Fund.

What's the current price of Endocyte Fund?
As of the end of day on the 2019-01-18, the price of an Endocyte (ECYT) share was $23.99.

What is the 52-week high and low for Endocyte Fund?
The 52-week high for Endocyte Fund is $24.00 and the 52-week low is $2.81.
Click to get the best stock tips daily for free!

About Endocyte

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trials to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of ad... ECYT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT